Apilimod mesylate by OrphAI Therapeutics for Amyotrophic Lateral Sclerosis: Likelihood of Approval

Apilimod mesylate is under clinical development by OrphAI Therapeutics and currently in Phase II for Amyotrophic Lateral Sclerosis.

Excessive weight gain during pregnancy linked to higher risk of death decades later

Pregnant people who gained more than the now-recommended amount of weight had a higher risk of death from heart disease or diabetes in the decades

October 20, 2023

Study uncovers missing piece in the complex nerve-network needed for left-right turns

Have you ever wondered what happens in the brain when we move to the right or left? Most people don’t; they just do it without

February 12, 2024

Expectation vs. Reality: Improving the Patient Payment Experience

Ryne Natzke, Chief Revenue Officer, TrustCommerce, a Sphere Company If you’ve ever worked behind the scenes at a provider organization, you likely gained a deep

October 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.